Nine Diagnostics has completed the Spring 2026 cohort of the Drive Accelerator, presenting its platform at the program’s Demo Day on May 13, 2026, in Charleston, South Carolina. Drive is run by SCbio in partnership with MassBio, and Nine Diagnostics’ participation was part of the Biomarkers and Diagnostics track, which concluded the eight-week program for this cohort.
Demo Day brought together life sciences investors and industry experts to hear pitches from the cohort’s companies. The program included a panel discussion on positioning early-stage companies for investment and strategic partnerships, featuring Holly Soares, global head of neuroscience and rare disease biomarkers at Roche, and Matt Clancey, director of new ventures and strategic alliances at Labcorp.
Over the eight weeks, Nine Diagnostics participated in curriculum modules led by industry experts, with track partners including Labcorp, Eli Lilly, K&L Gates, Maynard Nexsen, The Matchstick Group, and VentureSouth, alongside a dedicated mentor advisory board and structured introductions across the life sciences ecosystem.
For Nine Diagnostics, Drive provided structured engagement with the commercial partners, payers, and diagnostic infrastructure providers central to translating the company’s AI-enabled multi-omic nanosensor platform toward clinical deployment. Graduating from the program builds on the connections and positioning established since the company’s selection for the cohort in March 2026.
Read SCbio’s recap of Demo Day.
About Nine Diagnostics
Nine Diagnostics is an AI-enabled multi-omic nanosensor company advancing precision medicine. The platform simultaneously captures proteomic, metabolomic, and lipidomic signals alongside patient clinical context to generate a multi-omic fingerprint, using machine learning to identify disease-relevant patterns without requiring prior knowledge of which biomarkers matter. This enables pre-treatment patient stratification, on-treatment response monitoring, and post-treatment minimal residual disease detection. Founded by Freddy T. Nguyen, MD, PhD (CEO), Daniel A. Heller, PhD (CSO), and Mijin Kim, PhD (Scientific Advisor), Nine Diagnostics is based in Cambridge, Massachusetts.